Download Files:
Carfilzomib-d8
$450
Only 1000 item(s) left in stock.
Products Details
Product Description
– Carfilzomib-d8 is deuterium labeled Carfilzomib. Carfilzomib (PR-171) is an irreversible proteasome inhibitor with an IC50 of 5 nM in ANBL-6 and RPMI 8226 cells.
Web ID
– HY-10455S
Storage Temperature
– -20°C (Powder, protect from light)
Shipping
– Blue Ice
Applications
– Cancer-Kinase/protease
Molecular Formula
– C40H49D8N5O7
References
– [1]Russak EM, et al. Impact of Deuterium Substitution on the Pharmacokinetics of Pharmaceuticals. Ann Pharmacother. 2019;53(2):211-216.|[2]Dasmahapatra G, et al. Carfilzomib interacts synergistically with histone deacetylase inhibitors in mantle cell lymphoma cells in vitro and in vivo. Mol Cancer Ther. 2011 Sep;10(9):1686-97.|[3]Kuhn DJ, et al. Potent activity of carfilzomib, a novel, irreversible inhibitor of the ubiquitin-proteasome pathway, against preclinical models of multiple myeloma. Blood. 2007 Nov 1;110(9):3281-90.
CAS Number
– 1537187-53-3
Molecular Weight
– 727.96
Compound Purity
– 98.93
SMILES
– O=C([C@@H](NC([C@H](CC1=CC=CC=C1)NC([C@H](CC(C)C)NC([C@@H](NC(CN2C([2H])(C([2H])(OC([2H])(C2([2H])[2H])[2H])[2H])[2H])=O)CCC3=CC=CC=C3)=O)=O)=O)CC(C)C)[C@@]4(OC4)C
Clinical Information
– No Development Reported
Research Area
– Cancer
Solubility
– 10 mM in DMSO
Target
– Apoptosis;Autophagy;Isotope-Labeled Compounds;Proteasome
Pathway
– Apoptosis;Autophagy;Metabolic Enzyme/Protease;Others
Product type
– Isotope-Labeled Compounds
Disclaimer: All products are for Research use only unless clearly stated otherwise on the product datasheet. Datasheets provided on the website are drafts for reference purpose only and you are requested to always refer to the hard copy included in the kit for your experimentation. Agdia Products are available for delivery only in Canada.
